Amicus Therapeutics, Inc. Provides FDA Update For Fabry Disease Program
October 02, 2015 at 14:38 PM EDT
Shares of Amicus Therapeutics are down 40% today after the company admitted it will not be able to file an NDA for its Fabry Disease drug Migalastat this year.
